Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023

LAWRENCEVILLE, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
February 27, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer

The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ and CAMBRIDGE, MA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- IMUNON,...
May 16, 2022 08:00 ET | Source: Celsion Corporation

Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., May 16, 2022 ...
November 15, 2021 08:30 ET | Source: Celsion CORP

Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update

Balance Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Nov. 15, 2021 (GLOBE...
November 05, 2019 08:00 ET | Source: Celsion CORP

Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer

GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --...
October 22, 2018 09:20 ET | Source: Celsion CORP

Celsion Announces Publication Highlighting the Potential of Celsion's Gene-Mediated Immunotherapy to Improve Administration of IL-12 and Progression-Free Survival in Ovarian Cancer Patients

Analysis in peer-reviewed journal, Future Oncology, outlines the ability of GEN-1, a non-viral nanoparticle delivery system, to support persistent local production of IL-12 LAWRENCEVILLE, N.J,...